Genaera Corporation, a biopharmaceutical company, engages in the research and development of pharmaceuticals with focus on obesity, anti-angiogenesis, and respiratory diseases. The company's development programs comprise Trodusquemine, which is in preclinical trials for the treatment of obesity and metabolic disorders; Squalamine lactate, which is in phase II trials, for the treatment of malignant solid tumors; LOMUCIN, which is in phase II trials, used to treat the overproduction of mucus in chronic respiratory diseases; and interleukin-9, which is in phase II trials, is a respiratory treatment based on the discovery of a genetic cause of asthma. It is also developing various aminosterols for the treatment of inflammatory disorders. Genaera Corporation has collaborative agreements with MedImmune, Inc. and Laboratorios Bago SA. The company was founded in 1987 and is headquartered in Plymouth Meeting, Pennsylvania.